Malin Corporation

Update on contingent consideration receivable regarding Kymab

  • Jul 28 2026, 07:05 IST/BST
  • Colin Grant
  • Company Report
  • 6 page(s)
  • Sectors : Pharma and healthcare
  • Companies : Malin Corporation

Ratings and price correct at time of issue.

  • Malin Corporation

    Closing Price: 710c

  • RATING 29/09/15

  • PREVIOUS RATING N/A

Person's Name

Colin Grant

Analyst

DAVY VIEW

Malin has provided an update on its contingent consideration receivable regarding its former investee company, Kymab. Following a decision by Kymab’s owner, Sanofi, Malin will reduce the valuation of its remaining interest in Kymab to nil. This was 8% of Malin’s last reported net asset value (NAV) on February 23rd.

View full article

Download full report with analyst certification and important disclosures

Jul 28 2026, 07:05 IST/BST

Download